Unlike current treatments for AD, pharmacological inhibition of sEH focuses on reducing the neurodegenerative processes that trigger cognitive decline, neuroinflammation and, eventually, the clinical manifestations of dementia.23, 53. Here, EPHX2 is linked to dementia.